|
|
News Breaks | | | | November 11, 2012 | | 11:24 EDT |  | ABT | Abbott presents promising Phase 2b Interferon-free hepatitis C results
Results from Abbott's phase 2b clinical trial, "Aviator," demonstrated high sustained viral response rates at 12 weeks post-treatment, SVR12, in all 8- and 12-week arms, with combinations of direct acting antivirals, DAAs, given with and without ribavirin, RBV. Results will be presented at the President's Press Conference and the latebreaking clinical trials session at the Liver Meeting, the Annual Meeting of the American Association for the Study of Liver Disease, AASLD, in Boston. | |
|
News For ABT From The Last 14 Days Check below for free stories on ABT the last two weeks. |
|
|
| May 21, 2013 | | 08:03 EDT | | ABT | Abbott announces CE Mark for coronary drug eluting stent
 Subscribe for More Information | | | May 20, 2013 | | 10:11 EDT |  | ABT | On The Fly: Analyst Upgrade Summary
Subscribe for More Information | | | 06:01 EDT | | ABT | Abbott upgraded to Buy from Neutral at Goldman
Goldman upgraded Abbott to reflect accelerating growth driven by emerging markets, better growth and product mix, new product launches, and market share gains. Price target raised to $44 from $38. | | | May 9, 2013 | | 07:04 EDT | | ABT | Abbott announces CE Mark for A1c test
Subscribe for More Information | |
|
|
|
|
|
|
